Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
5Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Rocket Pharmaceuticals, Inc. (RCKT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
4Distinct source URLs
8High confidence
0.838Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Rocket Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CONTRACT-MANUFACTURING-ORGANIZATIONS
CONTRACT-MANUFACTURING-ORGANIZATIONS
90%
we plan to pursue multiple options including direct manufacturing as well as outsourcing production of the active pharmaceutical (drug substance) ingredients and final drug product manufacturing (dru…
Reciprocal relationship from RGNX graph: f the Company’s operating leases: As of December 31, 2025 2024 Weighted-average remaining lease term (years) 9.8 10.3 Weighted-average discount rate 5.7 % 5.7…
Rocket Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
BUYER
BUYER
92%
Pursuant to the PRV APA, the buyer has agreed to pay the Company $180 million, payable in cash, upon the closing of the sale.
CANTOR-FITZGERALD-CO
CANTOR-FITZGERALD-CO
92%
10.1 Sales Agreement, dated March 10, 2026, by and between the Company and Cantor Fitzgerald & Co.
CIRM
CIRM
92%
Through March 31, 2026, the Company has received total RP-A501 grants of $ 5.0 million from CIRM.
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
on, costs, and timing of clinical studies and development of product candidates will depend on a variety of factors, including: • the scope, rate of progress, and expense of ongoing clinical studies …
PRESENTATION-ROCKET-PHARMACEUTICALS-INC
PRESENTATION-ROCKET-PHARMACEUTICALS-INC
62%
) ( 261 ) Purchases of property and equipment ( 5,862 ) ( 16,436 ) ( 8,358 ) Net cash provided by/(used in) investing activities 131,706 ( 98,066 ) ( 69,326 ) Financing activities: Issuance of common…
Rocket Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
RCKT-DEBT-12074
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
RCKT-DEBT-12073
Warrants outstanding: 7051
90%
xbrl warrant detail from xbrl 2025-12-31.
RCKT-DEBT
Debt stack $24.8M
90%
Market cache reports total debt of $24.8M.
Rocket Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Rocket Pharmaceuticals, Inc..
Rocket Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
RCKT-OWNER-RTW-INVESTMENTS-LP
RTW INVESTMENTS, LP
90%
13F overlay lists RTW INVESTMENTS, LP as top holder; 200 tracked holders.
Rocket Pharmaceuticals, Inc. Extended Supply Chain Network
